Esperion · 10 hours ago
Accounting Associate
Maximize your interview chances
BiotechnologyHealth Care
Insider Connection @Esperion
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Manage the day-to-day cash and treasury functions, journal entries, and bank reconciliations
Participate in the month-end accounting close process in compliance with established reporting deadlines, including recording journal entries, preparing monthly balance sheet account reconciliations, and preparing management analyses
Manage compliance activities, including maintenance of pharmaceutical licenses, state and local qualifications, annual reports, and other notices
Support other SOX related tasks as needed
Support the SEC financial reporting tasks such as preparing footnotes and financial statements and assisting in audit- related activities
Support tax activities, including managing estimated payments and tax compliance with IRS rules
Maintain the general ledger chart of accounts
Assist on special projects as required by management and the finance team
Additional duties and responsibilities as assigned
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Degree in Accounting, Finance or related area; or equivalent combination of education and work experience
Must be very detail-oriented
Ability to be proactive and work in a fast-paced environment
Ability to multi-task
Strong communication skills
Proficient in Microsoft Office suite, especially Excel and Word
Preferred
Experience with Microsoft Great Plains a plus
Benefits
401(k) matching plan
Health insurance
Paid time off
Holidays
Company
Esperion
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Funding
Current Stage
Public CompanyTotal Funding
$852.55MKey Investors
Oberland CapitalLongitude Capital
2024-01-18Post Ipo Equity· $97.8M
2021-12-02Post Ipo Equity· $225M
2021-04-26Post Ipo Equity· $50M
Recent News
2024-11-20
2024-06-05
Company data provided by crunchbase